Stay updated on PD-L1+ NSCLC Clinical Trial: Pembrolizumab Combo
Sign up to get notified when there's something new on the PD-L1+ NSCLC Clinical Trial: Pembrolizumab Combo page.

Latest updates to the PD-L1+ NSCLC Clinical Trial: Pembrolizumab Combo page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedAdded Revision: v3.4.2; removed the previous funding notice and Revision: v3.4.1.SummaryDifference0.3%

- Check21 days agoChange DetectedA site-wide notice about government funding status was added, advising users to check cc.nih.gov and opm.gov for updates. The page version was updated to Revision: v3.4.1, replacing v3.4.0.SummaryDifference0.3%

- Check28 days agoChange DetectedGlossary toggle added and study-record metadata labels updated (including capitalization tweaks to 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data') with Revision: v3.4.0. No core content, outcomes, or eligibility criteria were changed.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision: v3.3.4 was added and Revision: v3.3.3 was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check63 days agoChange DetectedAdded a comprehensive list of study locations across the United States and abroad (including numerous US states and international regions) and updated the document revision to v3.3.3.SummaryDifference2%

- Check84 days agoChange DetectedStudy status changed from Active, not recruiting to Completed; enrollment updated from 120 (Estimated) to 102 (Actual), with related dates adjusted accordingly.SummaryDifference0.4%

Stay in the know with updates to PD-L1+ NSCLC Clinical Trial: Pembrolizumab Combo
Enter your email address, and we'll notify you when there's something new on the PD-L1+ NSCLC Clinical Trial: Pembrolizumab Combo page.